Related Experiment Video
Updated: Jun 24, 2025
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Imatinib- and Nilotinib-Induced Lichenoid Eruption in Chronic Myeloid Leukemia: A Rare Case Report
Meenakshi Sachdeva1, Jayanti Singh1, Surabhi Dayal1
1Department of Dermatology, Pandit Bhagwat Dayal Sharma Postgraduate Institute of Medical Sciences, Rohtak, Haryana, India.
Abstract:
Imatinib and nilotinib are inhibitors of tyrosine kinases (TKIs) generated from the bcr-abl fusion protein, c-Kit, and platelet-derived growth factor receptors. Cutaneous adverse effects (AEs) of TKI are the most frequent non-hematological sequelae. In our case, the common molecular target raises the possibility that cross-intolerance, in which similar AEs occur with both agents, can arise. We hereby report a rare case report on cross-intolerance of cutaneous AEs of imatinib and nilotinib in chronic myeloid leukemia.
Insights
This study reports a rare case of cross-intolerance to skin side effects between imatinib and nilotinib. These tyrosine kinase inhibitors (TKIs) are used for chronic myeloid leukemia, and similar adverse events occurred with both drugs.
Area of Science:
- Oncology
- Pharmacology
- Dermatology
Background:
- Imatinib and nilotinib are tyrosine kinase inhibitors (TKIs) targeting bcr-abl, c-Kit, and PDGF receptors.
- Cutaneous adverse effects (AEs) are common non-hematological side effects of TKIs.
- The shared molecular targets suggest potential for cross-intolerance between these drugs.
Observation:
- A rare case of cross-intolerance in cutaneous adverse effects was observed.
- The patient experienced similar skin side effects when treated with both imatinib and nilotinib.
Findings:
- This case highlights the potential for cross-intolerance of cutaneous AEs between imatinib and nilotinib.
- The shared molecular targets of these TKIs likely contribute to the observed cross-intolerance.
Implications:
- Clinicians should be aware of the possibility of cross-intolerance when switching between imatinib and nilotinib.
- Understanding shared AE profiles can guide treatment decisions and patient management in chronic myeloid leukemia.
- Further research may explore the mechanisms underlying TKI-induced cutaneous AEs and cross-intolerance.
